STING agonists have shown considerable promise in immunotherapy for tumors and chronic viral infections, whereas STING inhibitors have paved the way for novel treatments of inflammatory diseases, including NAFLD, ALD, IBD, and liver fibrosis. The gene discussed is STING1; the disease is Hepatic fibrosis.